Caffeine CitrateThird Party Manufacturing in India

Caffeine Citrate works by blocking central adenosine receptors, which normally inhibit respiratory drive. Antagonizing these receptors increases the sensitivity of the medullary respiratory center to carbon dioxide, stimulates central respiratory drive, and increases minute ventilation. Unlike other methylxanthines like theophylline, it features a wider therapeutic index and a longer half-life in neonates, minimizing the need for constant plasma drug monitoring. It is highly effective and well-tolerated for infant respiratory support.

Therapeutic Uses

• Apnea of Prematurity: Reduces the frequency of prolonged respiratory pauses and hypoxic episodes in premature neonates.
• Neonatal Extubation Support: Boosts respiratory drive to support successful weaning from mechanical ventilation.

Why Manufacturers Choose Caffeine Citrate

Engaging in Caffeine Citrate third party manufacturing in India positions pharma brands as trusted providers in the specialized neonatal intensive care unit market. Celesta Healthcare supports this delicate medical segment by ensuring our partner facilities are WHO-GMP certified and operate under strict particulate-free, sterile conditions. This ensures the refined compound under CAS number 69-22-7 is processed with high precision. Manufacturing within verified WHO-GMP lines guarantees excellent safety and consistent quality, helping your brand stand out in specialized pediatric and hospital sectors.